secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001104659-24-115300
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance Q3 product revenue $58.6M; net loss narrows to $0.28/shr; FY24 guidance reaffirmed
--------------------------------------------------------------------------------

- Q3 2024 product revenue $58.6M ($42.1M Amtagvi, $16.5M Proleukin); net loss $83.5M ($0.28/shr) vs $113.8M ($0.46/shr) YoY.
- Reaffirms FY24 total product revenue guidance of $160-$165M and FY25 guidance of $450-$475M.
- 146 patients infused with Amtagvi since Apr 2024 launch; 82 infusions in Q3; 56 ATCs onboarded, targeting 70 by year-end.
- Regulatory submissions accepted in EU, UK, Canada; potential approvals in 1H2025 (UK) and 2H2025 (EU, Canada).
- Enrollment accelerating in IOV-LUN-202 Phase 2 NSCLC trial; potential accelerated U.S. approval for lifileucel in NSCLC expected in 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924115300/0001104659-24-115300-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924115300/tm2427769d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-115300

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer